Does Molina Healthcare Cover Adderall?

What Is Adderall and Why Does Coverage Get Complicated?

Adderall is a fixed-ratio combination of amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The FDA's current labeling lists ADHD in patients as young as 3 years old for the immediate-release formulation and age 6 and older for Adderall XR. Coverage is complicated for two reasons: its Schedule II DEA classification and a patchwork of state Medicaid rules that Molina, as a managed-care organization, must follow.

Schedule II Status and Its Effect on Formularies

Because Adderall is a Schedule II controlled substance under the Controlled Substances Act, insurers and pharmacy benefit managers apply stricter utilization management than they do for non-controlled drugs. The DEA's scheduling framework requires specific prescribing quantities and prohibits automatic refills. Molina carries these requirements into its formulary management by mandating prior authorization (PA) for almost every stimulant on its drug lists.

Generic vs. Brand Coverage

Generic amphetamine salts became widely available after Shire's patent on Adderall expired. Because Molina's formulary design generally follows a generic-first philosophy, generic amphetamine salts IR and XR are typically placed on Tier 2 (preferred generic), while brand-name Adderall and Adderall XR often sit on Tier 3 or Tier 4 (non-preferred brand). Choosing the generic, when therapeutically appropriate, can reduce or eliminate out-of-pocket costs on most Molina plans.

Molina Medicaid Plans: Coverage Rules by State

Molina Healthcare operates Medicaid managed-care contracts in 18 states as of 2025. ADHD stimulants, including amphetamine salts, are covered as a required benefit on Medicaid in the majority of these states because ADHD is a recognized psychiatric diagnosis with evidence-based pharmacotherapy. The American Academy of Pediatrics 2019 Clinical Practice Guideline for ADHD recommends FDA-approved medications as first-line pharmacotherapy for children aged 6 and older, with behavioral therapy added for ages 4 to 5. That guideline (Wolraich et al., Pediatrics 2019) underpins why state Medicaid programs are generally required to cover stimulants when medically necessary.

Prior Authorization Requirements on Medicaid

On Molina Medicaid plans, prior authorization for Adderall or its generics typically requires:

• A confirmed ADHD diagnosis from a licensed prescriber (physician, NP, or PA depending on state scope-of-practice laws)
• Documentation of symptom duration, functional impairment, and diagnostic criteria consistent with DSM-5
• For adults (age 18 and older), many Molina Medicaid states require an additional clinical note confirming adult ADHD onset before age 12, consistent with DSM-5 criteria
• Some states require a psychiatric or neuropsychological evaluation before PA is approved for adults

The Medicaid PA process is governed by the federal requirement that decisions for non-urgent requests be made within 14 days, and within 72 hours for expedited requests, per 42 CFR §438.210.

Step Therapy on Molina Medicaid

Several Molina Medicaid states require step therapy before approving brand-name Adderall. This means a member must try and document an inadequate response to generic amphetamine salts before Molina will authorize the brand. Most step-therapy protocols require a 30-day trial. If the generic causes adverse effects (for example, a documented allergy to a dye in one manufacturer's tablet), the prescriber can submit a medical necessity exception to bypass step therapy.

Quantity Limits

Molina Medicaid plans commonly impose a quantity limit of 30 tablets or capsules per 30-day supply for immediate-release formulations and 30 capsules per 30-day supply for XR formulations. Exceeding these limits requires a separate quantity limit exception PA.

Molina Medicare Part D Plans: What Seniors and Disabled Members Need to Know

Adderall is listed on Molina's Medicare Part D formularies, though coverage rules differ from Medicaid. Medicare Part D plans are governed by CMS formulary requirements, which mandate that a plan's formulary include drugs in all USP drug categories, including CNS stimulants, as long as the plan covers at least two drugs in each subcategory. CMS Part D formulary guidance outlines these requirements.

Tier Placement on Molina Medicare Part D

On Molina's Medicare Advantage Prescription Drug (MAPD) and standalone Part D (PDP) plans, generic amphetamine salts typically land on Tier 2 (generic), with a $0 to $15 copay in the initial coverage phase (2025 benefit design). Brand Adderall XR is commonly placed on Tier 3 or Tier 4, with copays ranging from $40 to $95 per 30-day fill during the initial coverage phase depending on the specific plan and region.

Medicare Part D Prior Authorization for Stimulants

CMS requires that any Part D coverage restriction, including PA, be based on clinically supported criteria. For Medicare members, Molina's PA criteria for amphetamine salts typically require:

• An ADHD or narcolepsy diagnosis from a treating physician
• For narcolepsy: documentation consistent with ICSD-3 criteria, often including a sleep study result
• For ADHD in adults over 65: clinical documentation is especially important because ADHD prevalence estimates in older adults remain an area of active research, with one PLOS ONE analysis (Dobrosavljevic et al.) suggesting underdiagnosis in this cohort

The Medicare Coverage Gap and Stimulant Costs

The 2025 Medicare Part D redesign under the Inflation Reduction Act caps out-of-pocket drug spending at $2,000 per year for Part D enrollees. For members who have not yet met the catastrophic threshold, generic amphetamine salts are generally affordable at Tier 2 pricing. Brand Adderall XR can become expensive before the cap is reached, making generic substitution an important cost-control strategy.

Molina Marketplace (ACA) Plans: Stimulant Coverage Under Essential Health Benefits

Molina offers Qualified Health Plans (QHPs) on ACA Marketplaces in several states. Under the ACA, all QHPs must cover mental health and substance use disorder services at parity with medical and surgical benefits, per the Mental Health Parity and Addiction Equity Act (MHPAEA). The HHS MHPAEA resource page explains how parity applies to prescription drugs.

ADHD is classified as a mental health condition, so formulary restrictions on stimulants must not be more restrictive than those on comparable medical drugs. This means Molina cannot impose PA requirements on Adderall that are more burdensome than, say, PA requirements on a cardiovascular drug at a similar tier, without a clinically justified reason.

Formulary Tiers on Molina Marketplace Plans

Molina's Silver and Gold Marketplace plans in most states place generic amphetamine salts on Tier 2 with copays between $10 and $30 per 30-day fill after the deductible is met. Bronze plans typically require the member to pay the full negotiated price until the deductible is satisfied, which can range from $15 to $60 for generics depending on the pharmacy.

Cost-Sharing Reduction (CSR) Plans

Members who qualify for cost-sharing reductions (household income 100% to 250% of the federal poverty level) and enroll in a Silver plan receive enhanced cost-sharing. On CSR Silver plans, generic amphetamine salts can cost as little as $1 to $5 per fill, making this an important enrollment consideration for low-income adults with ADHD.

How to Get Prior Authorization Approved: A Step-by-Step Guide

Prior authorization for Adderall through Molina is not automatic, but approval rates improve substantially when the prescriber submits complete clinical documentation. A 2022 AMA survey found that 94% of physicians reported PA delays in patient care, underscoring the importance of submitting thorough documentation on the first attempt.

Step 1: Confirm the Drug Is on the Formulary

Before starting a PA, the prescriber or their staff should verify that the specific drug (generic amphetamine salts IR or XR, or brand Adderall) is on the member's current plan-year formulary. Formularies change annually. The member's Evidence of Coverage (EOC) document or Molina's online formulary search tool confirms tier placement and any utilization management flags.

Step 2: Gather Required Clinical Documentation

Molina's PA request form for stimulants typically asks for:

• The member's full diagnosis with DSM-5 or ICD-10-CM code (F90.0 for predominantly inattentive ADHD, F90.1 for predominantly hyperactive-impulsive, F90.2 for combined presentation)
• Age of symptom onset and duration of diagnosis
• Previous medications tried, doses used, duration of therapy, and reason for discontinuation
• Current symptom severity, often documented with a validated rating scale such as the Adult ADHD Self-Report Scale (ASRS) or the Conners Rating Scale for children, the ASRS is referenced in ADHD clinical literature (Kessler et al., Psychological Medicine 2005, N=154 validation study)
• Any comorbid conditions (anxiety, depression, substance use history) that may affect the PA decision

Step 3: Submit the PA and Track the Timeline

PA requests can be submitted by the prescriber's office via fax, phone, or Molina's provider portal. Federal law requires Molina to respond to standard requests within 14 calendar days and to expedited requests within 72 hours. Expedited status applies when the standard timeline could seriously jeopardize the member's health, as defined by 42 CFR §438.210(d).

Step 4: If Denied, File an Appeal

If Molina denies the PA, the member and prescriber have the right to appeal. The appeal process has multiple levels:

1. Internal appeal (Molina's own review, typically 30 days for standard, 72 hours expedited)
2. External Independent Medical Review (IMR), required in most states after the internal appeal is exhausted
3. State fair hearing, available for Medicaid members who disagree with the final managed-care determination

Research on PA appeals outcomes shows that a meaningful proportion of denials are overturned when complete documentation is submitted. A 2021 OIG report found that Medicare Advantage plans overturned 75% of their own prior authorization denials upon appeal, suggesting that initial denials are not always the final word.

Alternatives If Adderall Is Not Covered or Not Approved

If Molina denies coverage for Adderall or its generics, several FDA-approved alternatives treat ADHD and may have different formulary status.

Non-Stimulant ADHD Medications

• Atomoxetine (Strattera generic): A non-stimulant NRI approved for ADHD in adults and children age 6 and older. Generic atomoxetine is available and typically sits on Tier 2 on most Molina formularies. A Cochrane review (Cortese et al., 2016) of 19 trials found atomoxetine superior to placebo for ADHD symptoms in adults (standardized mean difference 0.40, 95% CI 0.29 to 0.52).
• Viloxazine ER (Qelbree): Approved in 2021 for ADHD in patients ages 6 and older (and adults in 2022). It is a selective norepinephrine reuptake inhibitor. Formulary placement varies widely; many Molina plans require PA and step therapy through atomoxetine first.
• Guanfacine ER (Intuniv generic): An alpha-2A agonist approved as monotherapy or adjunctive therapy for ADHD in ages 6 to 17. Generic guanfacine ER is generally on Tier 2 and does not carry Schedule II restrictions.
• Clonidine ER (Kapvay generic): Similar mechanism to guanfacine, approved for ADHD ages 6 to 17. Often placed on Tier 1 or Tier 2 with no PA required.

Other Stimulant Options

If Adderall is denied but stimulant therapy is medically necessary, the prescriber may request methylphenidate products (Ritalin, Concerta, generics) or lisdexamfetamine (Vyvanse, now generic as of 2023). The FDA's approval of lisdexamfetamine generic opened lower-cost options that Molina has begun adding to formularies in several states.

Manufacturer Patient Assistance

Takeda's patient assistance program for Vyvanse (now largely academic given generic availability) and Shire's historical programs have been replaced by manufacturer copay cards. These cards do not work with Medicaid plans but may reduce costs on commercial Marketplace plans if coverage is denied or cost-sharing is high.

ADHD Prevalence and the Stakes of Coverage Decisions

ADHD affects approximately 9.8% of U.S. Children ages 3 to 17, according to CDC national survey data, and an estimated 4.4% of adults, based on a national comorbidity survey replication (Kessler et al., American Journal of Psychiatry 2006, N=3,199). Untreated ADHD is associated with lower educational attainment, higher rates of workplace accidents, and elevated risk of substance use disorder. A 2015 meta-analysis in Lancet Psychiatry (Cortese et al., N=10,068 across 37 trials) ranked amphetamines as the most effective pharmacological treatment for adult ADHD on standardized mean difference, making coverage of these agents a direct health equity issue.

The American Academy of Child and Adolescent Psychiatry (AACAP) states in its 2007 Practice Parameter (reaffirmed 2020): "Stimulant medications are the first-line pharmacological treatment for ADHD." That AACAP practice parameter provides the clinical backbone that prescribers cite in PA letters to Molina.

Special Populations: What Molina's Coverage Rules Mean for Different Groups

Children and Adolescents

Molina Medicaid plans covering CHIP (Children's Health Insurance Program) members typically have the most straightforward PA pathways for stimulants in children, because pediatric ADHD has the strongest evidence base and state CHIP programs are legally required to cover medically necessary mental health services. The 2019 AAP guideline cited above recommends stimulant medication starting at age 6, making PA approval relatively routine when the prescriber submits complete documentation.

College Students

Young adults transitioning from parents' insurance to their own Molina Marketplace plan should verify formulary continuity before the plan year begins. If an existing Adderall prescription was covered under a prior plan, that coverage does not automatically carry over. Molina may require a new PA submission. Students should plan for at least a two-week administrative buffer.

Pregnant Women

The FDA assigns amphetamines a pregnancy risk category that reflects limited human data and animal studies showing fetal harm at high doses. A 2018 JAMA Psychiatry study (Bro et al., N=1,107,542 Danish births) found a small but statistically significant association between first-trimester amphetamine exposure and congenital malformations (adjusted OR 1.28, 95% CI 1.00 to 1.64). Molina's PA criteria in most states include a review of pregnancy status, and some states require additional documentation or a prescriber attestation of the risk-benefit discussion for pregnant members. Coverage is not automatically denied, but closer scrutiny should be expected.

Adults Over 65

Medicare Part D plans cover Adderall for adults of any age when the prescriber documents a valid ADHD or narcolepsy diagnosis. As noted earlier, clinical documentation of symptom onset before age 12 (for ADHD) is essential for PA approval in this population because Molina reviewers follow DSM-5 diagnostic criteria when evaluating requests.

How to Read Your Molina Formulary and Find Adderall's Status

Every Molina plan member receives an Evidence of Coverage document and has access to an online formulary search tool at Molina's member portal. The formulary lists each drug by generic name, brand name, tier, and any utilization management (PA, step therapy, quantity limit) flags.

When searching for Adderall:

• Search "amphetamine" to find generic amphetamine salts IR (immediate-release)
• Search "amphetamine XR" or "amphetamine extended" for XR generics
• Search "Adderall" to see if brand is listed separately (it often is, at a higher tier)

If the drug is marked "PA" in the utilization management column, a prior authorization is required before the pharmacy can fill the prescription. The formulary search also shows the member's expected copay at their specific tier and cost-sharing level.

Practical Tips to Reduce Out-of-Pocket Costs

Even with coverage, stimulant costs can add up. These strategies may reduce what a member pays:

• Use the generic. Generic amphetamine salts IR 20 mg #30 costs roughly $20 to $45 at major pharmacies with a GoodRx discount, which may be lower than a Tier 3 brand copay. GoodRx pricing data is not a primary medical source, but the underlying principle of generic substitution is supported by FDA generic drug policy.
• Ask about 90-day supplies. Many Molina plans offer a lower per-unit cost on 90-day mail-order fills for non-controlled drugs. Note: because Adderall is Schedule II, federal law limits fills to a 30-day supply in most states. Some states (California, for example) allow up to a 90-day supply for Schedule II drugs via special state law; check your state's pharmacy board rules.
• File a formulary exception for a brand. If generic amphetamine salts are not therapeutically equivalent for a specific member (for example, documented bioequivalence issues with a particular manufacturer), the prescriber can file a formulary exception requesting brand-name coverage at a lower tier.
• Enroll in a Cost-Sharing Reduction Silver plan. If income qualifies, this plan design dramatically reduces copays, as described in the Marketplace section above.